drugset / Trial / NCT04693936

Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis

NCT04693936

Unknown 200 enrolled University of Crete
RandomizedParallel-groupOpen-labelDiagnostic

Summary

Hashimoto's disease (HT) and psoriasis (PsO) have a significant impact on patient's quality of everyday life, and early diagnosis is critical for the symptoms management and prognosis. There is evidence that HT and PsO share common metabolic pathways that relate to their pathogenesis, and are affected by dietary and lifestyle factors. Previous studies have identified potential metabolic biomarkers, although the small number of studies hamper their validation. Of note, most studies are not longitudinal thus do not capture the metabolic fluctuations in response to disease progression or dietary changes. Thus, the purpose of this study is to identify metabolic biomarkers of HT and PsO and study the role of epigenetic factors (diet and lifestyle) on the involved metabolic pathways . In addition, a comparative analysis of the disease-related quality of life (QoL) will be performed in relation to dietary changes to unravel possible links between the QoL and the associated metabolic pathways in HT and PsO.

Timeline

Start
2021-02-02
Primary completion
2024-09
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium-Magnesium combination Unknown
Subject Glutamine Other / unclassified
Subject Multivitamin Other / unclassified
Subject Omega 3-6-9 Unknown
Subject Probiotics Other / unclassified 40 unknown
Subject Vitamin C Other / unclassified